ELECTRONIC SUPPLEMENTARY INFORMATION

Vancomycin dimer formation between analogues of bacterial peptidoglycan surfaces probed by force spectroscopy

Matthew Batchelor, a Dejian Zhou, Matthew A. Cooper, Chris Abell and Trevor Rayment

^a Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK.

^b School of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS2 9JT, UK.

^c Institute for Molecular Bioscience, The University of Queensland, Brisbane, 4072, Australia.

^d School of Chemistry, University of Birmingham, Birmingham, B15 2TT, UK.




Fig. S1 Illustration of the specific interactions between vancomycin and Ac₂-L-Lysyl-D-Alanyl-D-Alanine (Ac₂-KDADA). The broken lines indicate specific hydrogen bonds. Mutation of the terminal D-Alanine to D-Lactate (as in the case of KDADLac) removes a hydrogen bond (second from the left) which results in the significantly weaker binding (K_d increased by ~ 3 orders of magnitude) associated with bacterial resistance to vancomycin. D. H. Williams and B. Bardsley: The vancomycin group of antibiotics and the fight against resistant bacteria, *Angew. Chem., Int. Ed.*, 1999, **38**, 1173–1193. Copyright Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission.




Fig. S2 An example of a Scatchard plot drawn to directly calculate K_d from equilibrium measurements at different analyte concentrations.




Fig. S3 The effect of increasing the flow rate from 10 to 50 μ l min⁻¹ on the dissociation rate of vancomycin from a 1 : 9 **1** : **4** surface.




Fig. S4 The effect of introducing AcKdAdA (concentrations in μ M in brackets) on the binding profile of a 1 μ M solution of vancomycin to a 1 : 9 1 : 4 surface.




Fig. S5 Overlaid sensorgrams showing typical SPR responses to vancomycin solutions (concentrations in μ M in brackets) for a 1 : 9 2 : 4 (KDALA) surface.




Fig. S6 Histograms of adhesion forces collected using the same KDADA-modified probe in a PBS solution containing 1 μ M vancomycin on a: (a) KDADA surface (n=249), (b) KDALA surface (n=248), (c) KDADLac surface (n=500), and (d) PEG-OH surface (n=500).




Fig. S7 Histograms of adhesion forces collected using the same KDADA probe-surface combination in PBS solutions containing: (a) 1 μ M vancomycin (n=500), (b) 1 μ M vancomycin and 50 μ M AcKDADA (n=500), (c) 1 μ M vancomycin (n=500), and (d) 50 μ M AcKDADA (n=500).




Fig. S8 Histograms of adhesion forces collected using the same KDADA probe-surface combination in PBS solutions containing: (a) 0 nM vancomycin (n=500), (b) 1 nM vancomycin (n=500), (c) 10 nM vancomycin (n=498), (d) 100 nM vancomycin (n=500), (e) 1 μM vancomycin (n=500), (f) 10 μM vancomycin (n=500), (g) 100 μM vancomycin (n=499), and (h) 0 nM vancomycin, after rinsing with buffer (n=499).

Scheme S1 Synthesis of compound 5

DZ-4. A mixture of 13 M NaOH (1.7 mL, 21.5 mmol) and tri(ethylene glycol) (16.11 g, 105 mmol) was stirred in an oil bath at 100 °C under an atmosphere of argon for 30 minutes. 11-Bromoundec-1-ene (5 g, 21.5 mmol) was then added. After 24 hours, the reaction mixture was cooled and extracted with hexane. Concentration of the combined hexane extracts by rotary evaporation at reduced pressure gave a yellow oil containing a mixture of mono and diether, according to analysis by 1 H NMR spectroscopy. Purification by column chromatography on silica gel (EtOAc) gave (4.4 g, 68%) of ether **DZ-4**, R_f (EtOAc) 0.51.

Ph₃CS(CH₂)₁₁(OCH₂CH₂)₃OCH₂COOH **DZ-27** (5)

IR v_{max} (film)/cm⁻¹ 3464(O-H), 3074(C-H), 1639(C=C), 1121(C-O); ¹H NMR δ ppm (400 MHz, CDCl₃) 1.16-1.33 (m, 12H, 6CH₂), 1.50 (p, J = 7.0 Hz, 2H, C**H**₂), 1.95 (q, J = 7.0 Hz, 2H, C**H**₂-), 2.94 (s, br, 1H, -OH), 3.37 (t, J = 7.0Hz, 2H, -C**H**₂-PEG), 3.47-3.67 (m, 12H, 3PEG), 4.81-4.93 (m, 2H, C**H**₂=CH-), 5.65-5.77 (m, 1H, CH₂=C**H**-). ¹³C NMR (100 MHz, CDCl₃) δ ppm 139.46 (-

CH=CH2), 114.44 (-CH=C**H**₂), 72.92, 71.86, 70.95, 70.92, 70.69, 70.35 (6 PEG C), 61.97 (-CH₂-PEG), 34.11, 29.91, 29.85, 29.77, 29.75, 29.43, 29.24, 26.39.

DZ-23. Sodium hydride (520 mg, 13 mmol, 60% suspension in mineral oil) was added to a solution of undec-1-en-11-yltri(ethylene glycol) **DZ-4** (2.6 g, 8.6 mmol) in dry DMF (3 mL) at 0 $^{\circ}$ C. The resulting mixture was stirred at 0 $^{\circ}$ C for 10 minutes, then ethyl-bromoacetate (1.92 mL, 13 mmol) was added under a nitrogen atmosphere. The reaction mixture was stirred at room temperature for 3 hours. An additional amount of ethyl-bromoacetate (1.92 mL, 13 mmol) was added and the reaction heated at 40 $^{\circ}$ C overnight. On cooling, the reaction mixture was extracted into EtOAc (3 \times 20 mL), washed with distilled water (2 \times 20 mL) and with brine (20 mL), dried over anhydrous Na₂SO₄ and evaporated to dryness. Purification by column chromatography on silica gel (hexane/EtOAc 1:1) gave the ester **DZ-23** (4.5 g, impure, maybe including ethyl-bromoacetate and mineral oil), R_f (silica gel, hexane/EtOAc 1:1) 0.34.

¹H NMR (400 MHz, CDCl₃) δ ppm 1.20-1.37 (m, 15H, (CH₂)₆ + CH₃), 1.48-1.58 (m, 2H, C**H**₂), 1.95-2.03 (m, 2H, C**H**₂), 3.40 (t, J = 6.9 Hz, 2H, -C**H**₂PEG), 3.51-3.71 (m, 12H, 3PEG), 4.10 (s, 2H, -CH₂COOEt), 4.17 (q, J = 7.1 Hz, 2H, -COOCH₂), 4.85-4.96 (m, 2H, H₂C=), 5.70-5.82 (m, 1H, =CH-).; ¹³C NMR (100 MHz, CDCl₃) δ ppm 170.81 (C=O), 139.55 (-CH=), 114.46 (H₂C=), 71.88, 71.26, 71.00, 70.95, 70.42, 69.09 (PEG, C), 61.12 (-O-PEG), 34.15, 29.99, 29.88, 29.81, 29.78, 29.42, 29.28, 26.44, 14.57 (CH₃). **LCMS** (ES⁺): 389 (40%, [M+H]⁺), 407 (100%, [M+NH₄]⁺.

DZ-24. To 8 Pyrex tubes, each containing undec-1-en-11-yltri(ethylene glycol)-ethyl ester **DZ-23** (0.39 g, 1 mmol) in MeOH (5 mL) was added AIBN (30 mg), and thioacetic acid (0.12 mL, 2.4 mmol). Each tube was bubbled with N_2 for 2 minutes. The tubes were then sealed, put into a photochemical reactor and irradiated with a mercury lamp at 340 nm for 24 hours. On cooling, the tubes were taken out from the reactor. The reaction mixtures were then combined and evaporated to dryness. The solvent was then removed under reduced pressure and the residue

purified by chromatography on a silica gel column (hexane/EtOAc 2:1) to obtain the ester **DZ-24** as a slightly yellowish oil (3.36 g, 90%).

¹H NMR (400 MHz, CDCl₃) δ ppm 1.18-1.32 (m, 17H, (CH₂)₇+CH₃), 1.46-1.56 (m, 2H, CH₂), 2.27 (s, 3H, CH₃(C=O)S), 2.81 (t, 2H, J = 7.2 Hz, AcSCH₂-), 3.40 (t, J = 7.0 Hz, 2H, -CH₂PEG), 3.50-3.70 (m, 12H, 3PEG), 4.10 (s, 2H, -CH₂COOEt), 4.17 (q, J = 7.1 Hz, 2H, -COOCH₂); ¹³C NMR (100 MHz, CDCl₃) δ ppm 201.30 (CH₃(C=O)S-), 175.72 (C=O), 76.78, 76.13, 75.87, 75.29, 73.97, 73.12 (PEG, C), 66.03, 35.90, 29.99, 29.88, 29.81, 29.78, 29.42, 29.28, 26.44, 14.57 (CH₃). **LCMS** (ES⁺), 465 (40%, [M+H]⁺), 482 (100%, [M+NH₄]⁺).

DZ-25. To 1-thioacetateundec--11-yltri(ethylene glycol)-ethyl ester **DZ-24** (3.36 g, 7.2 mmol) in MeOH (10 mL) was added 0.1 M HCl (8 mL). The reaction mixture was heated at reflex under N₂ for 8 hours. The solvent was then evaporated and the residue purified by column chromatography on silica gel (hexane/EtOAc 1:1) obtained the acid **DZ-25** as a slightly yellowish oil (2.70 g, 92%).

¹H NMR (400 MHz, CDCl₃) δ ppm 1.20-1.40 (m, 14H, 7C**H**₂), 1.50-1.61 (m, 4H, 2C**H**₂), 2.49 (q, 2H, J = 7.2 Hz, -C**H**₂SH), 3.41 (t, 2H, J = 6.9 Hz, -C**H**₂PEG), 3.51-3.75 (m, 15H, 3**PEG** + C**H**₃), 4.15 (s, 2H, -C**H**₂COOMe); ¹³C NMR (100 MHz, CDCl₃) δ ppm 170.68 (C=O), 71.31, 70.69, 70.40, 70.34, 69.81, 68.40 (PEG, C), 51.57 (CH₃), 33.82, 29.39, 29.32, 29.27, 28.83, 28.14, 25.85, 24.43. **LCMS** (ES⁺): 409 (45%, [M+H]⁺), 426 (100%, [M+NH₄]⁺.

DZ-26. 2-[11-Tritylthiolundec-1-yltri(ethylene glycol)] acetic acid **4.7** was synthesized according to the literature procedure (see Houseman, B. T.; Mrksich, M. *J. Org. Chem.* **1998**, *63*, 7552-7555.), and purified by column chromatography on silica gel (hexane/EtOAc 1:1) (Rf = 0.23 (1:1 EtOAc/hexane) as a slightly yellow oil.

¹H NMR (400 MHz, CDCl₃) δ ppm 1.09-1.41 (m, 16H, 8C**H**₂), 1.51-1.60 (m, 2H, C**H**₂), 2.11 (t, 2H, J = 7.2 Hz, Ph₃CSC**H**₂), 3.42 (t, 2H, J = 6.9 Hz, -C**H**₂PEG), 3.54-3.75 (m, 15H, 3**PEG** + C**H**₃), 4.15 (s, 2H, -C**H**₂COOMe), 7.15-7.21 (m, 3H, 3Ph-**H** para), 7.22-7.30 (m, 6H, 6 Ph-**H**),

7.37-7.42 (m, 6H, 6Ph-**H**); ¹³C NMR (100 MHz, CDCl₃) δ ppm 171.53 (**C**=O), 145.70, 130.22, 128.42, 127.11 (Ph-**C**), 72.17, 71.55, 71.26, 71.20, 70.67, 69.26 (PEG-**C**), 52.42 (**C**H₃), 32.64, 30.26, 30.18, 30.11, 30.03, 29.81, 29.64, 29.21, 26.71. **LCMS** (ES⁺): 668 (80%, [M+NH₄]⁺).

DZ-27 (5). The synthesis of DZ-27 (**5**) was prepared following a literature procedure and purified by followed by purified by column chromatography on silica gel (10% MeOH/CH₂Cl₂, Rf = 0.27) as a slightly yell oil.


¹H NMR (400 MHz, CDCl₃) δ ppm 1.08-1.30 (m, 14H, 7C**H**₂), 1.31-1.41 (m, 2H, C**H**₂), 1.50-1.60 (m, 2H, C**H**₂), 2.11 (s, 2H, J = 7.1 Hz, -C**H**₂SCPh₃), 3.42 (t, J = 7.0 Hz, 2H, -C**H**₂PEG), 3.54-3.72 (m, 12H, 3**PEG**), 4.13 (s, 2H, -C**H**₂COOH), 7.15-7.22 (m, 3H, 3Ph-**H**), 7.22-7.30 (m, 6H, 6Ph-**H**), 7.36-7.42 (m, 6H, 6Ph-**H**). ¹³C NMR (100 MHz, CDCl₃) δ ppm 173.06 (C=O), 145.61, 128.97, 127.16, 125.86, (Ph-**C**), 70.98, 69.73, 69.55, 69.51, 69.36, 69.12 (PEG, C), 31.39, 28.94, 28.88, 28.81, 28.57, 28.40, 27.96, 25.39. HRMS, (TOF MS), found 659.3391, required for $C_{38}H_{52}O_6SNa [M+Na]^+$, 659.3382, dev., 1.27 ppm. R_f (10% MeOH/CH₂Cl₂), 0.27.

Synthesis of peptide-thiols


Scheme S2 Synthesis of the KdAda-modified thiol (1). Conditions: (a) piperidine, DMF; (b) Fmoc-dAla-OH, EDC, HOBt, DMF; (c) Fmoc-lLys-OH, EDC, HOBt, DMF; (d) Fmoc-Ahx-OH, EDC, HOBt, DMF; (e) **5**, EDC, HOBt, DMF; (f) TFA, DCM, Et₃SiH; (g) TFA, CHCl₃, BuSH.

NMR and HR-MS Spectra of the peptide-thiols

High resolution mass spectroscopy **KDADA**




¹H NMR (500 mHz) KDADA in MeOD



¹³C NMR (125 MHz) KDADA in MeOD

Standard 13C DRX500 D-Ala-HY2-4 D. Zhou - CA




¹³C NMR (APT) KDADA in MeOD


Standard APT DRX500 D-Ala-HY2-4 D. Zhou - CA

D. Zhou - CA






High resolution mass spectroscopy **KDADLac**



1H-NMR (500 MHz) **KDADLac in MeOD**


Standard 1H DRX500 Lac-RE1-4 D. Zhou - CA




	Date Benevations	
MAME	Data Parameters ca-lac-rel-4	
EXPNO	Ca-1ac-re1-4	
PROCNO	1	
PROCNO	1	
	uisition Parame	ters
Date_	20010619	
Time	17.25	
INSTRUM	drx500	
PROBHD	5 mm Dual 13	
PULPROG	zg30	
7D	65536	
SOLVENT	MeOH	
NS	56	
DS	0	
SWH	6510.417	
PIDRES	0.099341	
AQ RG	5.0332146	
DW DW	128	
DE	76.800	
TE	300.0	usec
D1	2.00000000	
	2.0000000	acc
	=== CHANNEL f1	
NUC1	18	
P1	11.70	usec
PL1	0.00	
SF01	500.0527503	MHZ
F2 - Proc	essing paramete	ers
SI	32768	
SF	500.0500193	MHz
WDW	EM	
SSB	0	
TB	0.10	Hz
GB	0	
PC	1.00	
1D NMR pl	ot parameters	
CX	30.00	CTI.
F1P	12.000	ppm
	6000.60	Hz
F1		
F2P	-0.400	
F1 F2F F2	-200.02	Hz
F2P		Hz ppm/cm

¹³C-NMR (125 MHz) **KDADLac in MeOD**


Standard 13C DRX500 Lac-RE1-4 D. Zhou - CA




¹³C-NMR APT **KDADLac in MeOD**













High resolution mass spectroscopy **KDALA**



1H-NMR (500 MHz) **KDALA in MeOD**







Standard APT DRX500 L-Ala-HY3-6 D. Zhou - CA

¹³C-NMR APT **KDALA in MeOD**

